Radcliffe Capital Management’s Orion Biotech Opportunities Corp. Warrant ORIAW Stock Holding History

Radcliffe Capital Management’s Portfolio ORIAW Stock Details ORIAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-80,001	Closed	-$5.2K	–	678
2023 Q1	$5.2K	Hold	80,001	–	–	﹤0.01%	613
2022 Q4	$804K	Hold	80,001	–	–	0.03%	726
2022 Q3	$788K	Hold	80,001	–	–	0.02%	986
2022 Q2	$779K	Buy	80,001 +1	+0%	–	0.02%	1043
2022 Q1	$779K	Hold	80,000	–	–	0.02%	1043
2021 Q4	$780K	Hold	80,000	–	–	0.02%	901
2021 Q3	$782K	Buy	+80,000	New	+$104K	0.02%	765

Radcliffe Capital Management's ORIAW Position: Q2 2023 in Review

Radcliffe Capital Management sold out of Orion Biotech Opportunities Corp. Warrant (ORIAW) in Q2 2023, closing a stake of 80,001 shares — an estimated $5.2K sold.

Radcliffe Capital Management first reported a position in ORIAW in Q3 2021 and held it in 7 quarters. The position peaked at $804K in Q4 2022. 0 funds tracked by Wall St. Rank hold ORIAW as of Q2 2023.

Radcliffe Capital Management reported no remaining Orion Biotech Opportunities Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Radcliffe Capital Management sold 80,001 Orion Biotech Opportunities Corp. Warrant shares in Q2 2023, an estimated $5.2K.
Radcliffe Capital Management first reported a position in Orion Biotech Opportunities Corp. Warrant in Q3 2021 and held it in 7 quarters.
Radcliffe Capital Management's Orion Biotech Opportunities Corp. Warrant position peaked at $804K in Q4 2022.
0 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Warrant as of Q2 2023.

Based on Radcliffe Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.